Jefferson University Hospitals

Physician Profile

Bijoyesh Mookerjee, MD

Jefferson University Physician

Academic Title: Clinical Assistant Professor

Specialties
Hematology - Medical Oncology
Medical Oncology
Medical Oncology - Bone Marrow Transplant
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Years in Practice

20

Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Education

  • Armed Forces Medical College, Medical School

Internship

  • St. Stephen's Hospital

Residency

  • SUNY Downstate Medical Center - Brooklyn

Fellowship

  • National Cancer Institute
  • SUNY Downstate Medical Center - Brooklyn

Recent Publications

Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): Results of a phase 3, open-label, randomised trial

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease

Adenovirus DNA polymerase is recognized by human CD8+T cells

Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy

In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy

T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions